- Tivic Health has acquired the manufacturing and development assets of Scorpius Holdings and launched Velocity Bioworks as a new CDMO subsidiary.
- The acquisition supports U.S.-based manufacturing for Entolimod™, enhances Tivic’s biologics development capabilities and introduces new revenue opportunities.
Tivic Health has acquired the strategic manufacturing and development assets of Scorpius Holdings and launched Velocity Bioworks, a wholly owned subsidiary that will provide contract development and manufacturing services to Tivic and other biotechnology companies. The company said the initiative secures a U.S.-based site for production of its lead drug candidate Entolimod™ as it advances towards a Biologics License Application with the U.S. Food & Drug Administration.
The new subsidiary is intended to increase development speed for other Entolimod and Entolasta indications, including programmes for neutropenia and advanced cancer. Tivic noted that Velocity Bioworks will focus on the production of cellular and biologic therapies and will create new revenue opportunities through external CDMO partnerships. Tivic validated the Entolimod cell line at the same site earlier in 2025, progressing its path toward cGMP manufacturing.
Chief Executive Officer Jennifer Ernst said the move aligns with the company’s expansion into biologics. “Tivic has entered a new era… our new CDMO built for fast, high-quality biologic production that can serve both us and third-party biotech companies,” she stated. She added that bringing manufacturing capabilities in-house is designed to reduce development costs and avoid delays associated with outsourcing.
The transaction is backed by financing led by 3i, LP. This includes $16 million in debt financing for asset purchases and facility improvements, and up to $75 million in preferred convertible equity, with $18 million available in near-term tranches. An affiliated entity is also expected to provide a $50 million equity line of credit to support future capital needs.
Tivic will grant stock options to 45 new employees hired through the acquisition under Nasdaq Listing Rule 5635(c)(4). Velocity Bioworks will operate from a facility in San Antonio and will offer analytical testing, process development and manufacturing services aimed at accelerating biologic programmes to the clinic.
